Antibiotic resistance 2024 | Antibiotics Conference 2024 | Drug resistance | Bacterial infections | Intensive care units | Microbiology | Pharmacology | Infectious diseases | Resistance surveillance | Resistance epidemiology | Antibiotic resistance events 2024 |Canada | Conference series LLC Ltd

Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Antibiotics Resistance 2024

Antibiotics Resistance 2024

Antibiotics Resistance 2024 invites all the participants from all over the world to attend “10th International Conference on Antibiotics & Antibiotic Resistance’’ scheduled to be held on November 25-26, 2024 we are going to conduct this conference at Vancouver, Canada. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Antibiotics Resistance. The primary objective of this meeting is to compile researchers involved in antibiotic resistance prevention and control. The meeting will take a unified approach to research and it will bring about researchers specializing in different subjects related to antibiotic resistance.

Conference Series Ltd organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Details of Antibiotics Resistance 2024 Conferences in Canada:

Conference Name

Place

Date

Antibiotics Resistance 2024

Vancouver, Canada

November 25-26, 2024

 

VISA Requirement

Planning a Trip to VANCOUVER, BRITISH COLUMBIA, CANADA!! Attending Meeting!!!

Issue with VISA!!

Participants requiring a visa should apply immediately to the consular office or embassy in their country in order to avoid inconvenience. Please note that the visa application procedure can take some weeks.

The Program organizer can assist the attendees by processing official invitations upon request after registering for the conference. This letter of invitation, however, constitutes neither an obligation by the Local Organizing Committee to cover any travel and accommodation expenses, fees or other costs connected with attending the meeting and staying in Vancouver, Canada.

The deadline for requesting a Letter of Invitation is one month before traveling to Canada via. E-mail: antibiotics@eventsupporting.org

 

Why to attend?

Why to attend?

With members from around the world focused on learning about Antimicrobials & Antibiotic Resistance and its advances in making a better health; this is your best opportunity to reach the largest assemblage of participants from the Antimicrobials & Antibiotic Resistance Committee. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, new treatment techniques and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Antimicrobials & Antibiotic Resistance are hallmarks of this conference.

Benefits:

  • All the accepted speaker abstracts will be published in the respective supporting journals and receive DOI provided by CrossRef.
  • Global networking: In transferring and exchanging Ideas.
  • Networking with experts in your field.
  • Expert Forums.
  • Career Development Sessions.
  • Best Poster Awards.
  • Preconference and Conference Workshops.
  • Symposiums on Latest Research.

We invite all the participants to join in Vancouver, Canada to promote Antibiotics Resistance 2024 !

 

 

Sessions/Tracks

Track : 1 Antibiotics

Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.

Introduction to antibiotic uses and challenges

Basic principles of prescribing antibiotics

Mechanisms of bacteriostatic or bactericidal action

Antibiotic Use Linked to Type 1 Diabetes Diagnosis

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 2 Mechanisms and Evolution of Antibiotic Resistance

Antibiotic resistance is a growing concern in the field of medicine and public health. It refers to the ability of bacteria to survive and grow in the presence of antibiotics that were originally effective in killing or inhibiting their growth. The mechanism and evolution of antibiotic resistance is a complex process that involves genetic changes in bacteria over time. The evolution of antibiotic resistance is driven by the selective pressure imposed by the use of antibiotics. When antibiotics are introduced into an ecosystem, they kill susceptible bacteria, but some bacteria may possess resistance genes that allow them to survive and reproduce. These resistant bacteria then have a selective advantage over susceptible bacteria, leading to the proliferation of antibiotic-resistant strains. Additionally, the misuse and overuse of antibiotics in both human and animal populations contribute to the rapid evolution of resistance. The constant evolution of antibiotic resistance poses a significant threat to human health, as it limits the effectiveness of antibiotics in treating infections. It is crucial for healthcare providers to adopt responsible antibiotic prescribing practices and for researchers to develop new antibiotics and alternative treatment strategies to combat this growing problem.

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 3 Antibiotic-resistant Bacterial infections

Antibiotic-resistant bacterial infections are a serious and growing global health concern. These infections occur when bacteria become resistant to the drugs that were originally designed to kill or inhibit their growth. As a result, the effectiveness of antibiotics in treating these infections is greatly reduced, leading to prolonged illness, increased healthcare costs, and higher mortality rates. There are several factors contributing to the rise of antibiotic-resistant bacterial infections. The misuse and overuse of antibiotics, both in healthcare settings and in agriculture, play a significant role. When antibiotics are used unnecessarily or inappropriately, bacteria have more opportunities to develop resistance. Additionally, the spread of resistant bacteria between individuals and healthcare facilities can occur, further exacerbating the problem. Common infections such as urinary tract infections, pneumonia, and bloodstream infections are increasingly becoming more difficult to treat due to antibiotic resistance. In some cases, there may be limited or no effective treatment options available, leading to increased morbidity and mortality rates.

 

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 4 Microorganisms Producing Antibiotics

Microorganisms have long been recognized as a valuable source of antibiotics. Many bacteria and fungi have the ability to produce compounds that inhibit the growth of other microorganisms, providing them with a competitive advantage in their environment. These antibiotic-producing microorganisms have played a crucial role in the development of antibiotics that are used to treat bacterial infections in humans. Bacteria such as Streptomyces and Bacillus, as well as fungi like Penicillium and Aspergillus, are well-known producers of antibiotics. These microorganisms have the genetic machinery to synthesize complex molecules with antimicrobial properties. Through a process of biosynthesis, they produce and release these antibiotics into their surroundings. The discovery and isolation of antibiotic-producing microorganisms has been essential in the development of new antibiotics. Scientists have been able to study the chemical structures and mechanisms of action of these natural compounds, leading to the synthesis of modified or more potent versions of antibiotics.

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 5 Drug Discovery and Novel Delivery Technologies

In the prior most drugs have been invented either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new access has been to recognize how disease and infection are controlled at the molecular and physiological level and to mark specific entities based on this knowledge. The process of drug discovery involves the identification of candidates, characterization, screening, synthesis, and assays for therapeutic efficacy. Evolution of an existing drug molecule from a ordinary form to a novel delivery system can significantly improve its performance in terms of patient compliance, efficacy and safety. These days, drug delivery companies are engaged in the development of numerous platform technologies to get ambitious advantage, extend patent life, and increase market share of their products. Formerly a compound has displayed its value in these tests; it will begin the process of drug development prior to clinical trials.

Policies to stimulate drug development and discovery

Role of computational biology

Ligand binding studies

Transport (simulation studies)

Molecule mediating transport

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 6 Antimicrobial Therapy

An antimicrobial therapy kills or inhibits the growth of microorganisms such as bacteria, fungi, or protozoans. Antimicrobial agents are some of the most widely, and often used therapeutic drugs worldwide. It contributes significantly to the quality of life of many people and reduces the morbidity and mortality due to infectious disease. The remarkable success of antimicrobial therapy has been achieved with comparatively little toxicity and expense

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 07 Antibiotic Resistance: Opportunities and Challenges

Certain bacterial infections now oppose all antibiotics. The resistance problem may be reversible, but only if society begins to acknowledge how the drugs affect "good" bacteria as well as "bad". Historically, most antibacterials were used in hospitals, where they were integrated into surgical clothes and soaps to limit the spread of infection. More recently, however, those substances (including  triclosan, triclocarbon and such quaternary ammonium compounds as benzalkonium chloride) have been mixed into lotions, dish-washing detergents and soaps meant for general consumers. They have also been impregnated into such items as cutting boards, toys, high chairs and mattress pads.

 

Antibiotics and alternatives

Grand challenges – antimicrobial resistance

Systemic intervention – values, conflict and blue room resolution

Intervention against antimicrobial resistance – approaches and implementation

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 08 Antibiotic Prophylaxis

Antimicrobial prophylaxis is generally used by clinicians for the prevention of numerous infectious diseases. Optimal antimicrobial agents for prophylaxis should be nontoxic, inexpensive, bactericidal and active against the typical pathogens that can motive surgical site infection postoperatively. To maximize its effectiveness, intravenous perioperative prophylaxis should be carried out within 30 to 60 minutes before the surgical incision. Antimicrobial prophylaxis should be of short time to downturn toxicity and antimicrobial resistance and to reduce cost.

Prevention of microbial infection

Antibiotic selection

Advantages of long-acting antibiotics

Antibiotics in aquaculture

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 09 Antimicrobial Peptides

Antimicrobial peptides (AMPs), also called Host Defence Peptides (HDPs) are part of the innate immune response found among all classes of life. AMPs have a broad spectrum of targeted organisms ranging from viruses to parasites. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as Immunomodulatory

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 10 Antibiotics for Various Diseases and Infections

Antibiotics are amidst the most regularly recommended medications in modern medicine. Antibiotics are useless against viral infections. When you take antibiotics, follow the guidelines carefully. It is important to finish your medicine even if you feel improved. If you stop treatment too soon, some bacteria may survive and re-infect you. Do not save antibiotics for later or use someone else's prescription

Novel antibacterial drug discovery

Skin and soft tissue infections

Urinary tract infections

Acute diarrhea, gastroenteritis, and food poisoning (Campylobacteriosis)

Common gynecologic Infections

Fever and apparent acute central nervous system Infection

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 11 Pharmacology & Toxicology

Pharmacology and toxicology are two closely related fields that study the effects of drugs and other chemicals on living organisms. Pharmacology focuses on understanding how drugs interact with the body to produce therapeutic effects. It involves studying drug absorption, distribution, metabolism, and excretion, as well as their mechanisms of action and potential side effects. Pharmacologists also investigate drug-drug interactions and develop new medications to treat various medical conditions. Toxicology, on the other hand, examines the adverse effects of chemicals on living organisms. It involves studying the toxic properties of substances, including drugs, environmental pollutants, and industrial chemicals. Toxicologists aim to understand the mechanisms of toxicity, identify potential hazards, and evaluate the risks associated with exposure to these substances. They also develop strategies to prevent or minimize toxic effects and ensure the safety of drugs and other products.

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 12 Antibiotics: In Pregnancy and Lactation

Antibiotics are frequently recommended during pregnancy. The specific medication must be chosen carefully, however. Some antibiotics are prescribed to take during pregnancy, while others are not. Safety depends on various factors, including the type of antibiotic, when in pregnancy you take the antibiotic, how much you take and for how long. Antibiotics normally advised safe during pregnancy:  Ampicillin, Amoxicillin, Clindamycin, Erythromycin, Penicillin, Nitrofurantoin. Despite there's no direct clue that these antibiotics cause birth defects, additional research is needed. In the interim, use of these medications is still assured in some cases.

Safe use of anti‐infective agents

Current investigations in broad spectrum antibiotics

Antibiotics and neurological damage

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 13 Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs

The pharmacodynamics of an antimicrobial drug relates its pharmacokinetics to the time course of the antimicrobial effects at the site of the infection. Knowledge of the drug's antimicrobial pharmacodynamics effects provides a more rational basis for determination of optimal dosing regimens in terms of the dose and the dosing interval than do the minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) determined in vitro. This session mainly focus on pharmacokinetics, antimicrobial pharmacodynamics, the effect of pharmacodynamics on the emergence of resistant bacterial subpopulations, and the development of pharmacodynamics breakpoints for use in the design of trials of these drugs and in the treatment of infected patients

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 14 Immunology & Vaccines

Immunology and vaccines are closely interconnected, as vaccines harness the principles of immunology to protect individuals from infectious diseases. Immunology is the branch of science that focuses on understanding the immune system and its response to foreign substances, including pathogens. It studies how the immune system recognizes and eliminates pathogens, as well as how it develops memory to provide long-lasting protection against future infections. Vaccines, on the other hand, are biological preparations that stimulate the immune system to produce a protective response without causing the actual disease. They contain weakened or inactivated forms of pathogens, specific antigens, or genetic material that code for antigens. When administered, vaccines trigger an immune response, leading to the production of antibodies and activation of immune cells. This immune response enables the immune system to recognize and mount a rapid and effective defense against the actual pathogen if encountered in the future.

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 15 Infectious Diseases

Infectious diseases are illnesses caused by pathogenic microorganisms such as viruses, bacteria, parasites, or fungi that can be transmitted from one person to another either directly or indirectly (vector-borne). The invasion of disease-causing pathogens into an organism's body tissues, their growth, and the host tissues' response to the infectious agents and the toxins they produce are all considered to be infections. A condition brought on by an infection is referred to as an infectious disease, often known as a transmissible or communicable sickness. There are many different pathogens that can cause infections, but bacteria and viruses are the most prevalent ones. Hosts' immune systems can aid in their ability to combat disease. The medical specialty that deals with infections is referred to as infectious disease.

Influenza

Cryptosporidiosis

Vector-Borne Diseases

Legionnaires’ Disease

Human Metapneumovirus

Antibiotic-Resistant Diseases

Valley Fever

Immunity and Infectious Diseases

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 16 Developing Alternatives to Antibiotics

Alternatives to antibiotics are broadly defined as any substance that can be substituted for therapeutic drugs that are increasingly becoming ineffective against pathogenic bacteria due to antimicrobial resistance. Although antibiotics remain an essential tool for treating animal diseases on the farm, the availability of effective medical interventions to prevent and control animal diseases is one of the most significant challenges facing veterinary medicine in the 21st century. Phytochemicals as antibiotic alternatives to promote growth and enhance host health. Innovative drugs, chemicals, and enzymes within the animal production chain. Vaccines as alternatives to antibiotics for food producing animals. Also recent research provides numerous possibilities for the application nanomaterials in broad-spectrum eradication of pathogenic bacteria with many applications such as skin pathogen infection, implant sterilization, and wastewater treatment.

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

Track: 17 The Next Generation Approach of Antibiotics

As research into antibiotic resistance expands, it is important to adopt an explicitly proactive approach to antibiotic resistance identification and surveillance, as well as antibiotic therapy development. This proactive approach involves using a combination of functional metagenomics, next-generation sequencing and cutting-edge computational methods to monitor the evolution and dissemination of resistance before a given resistance determinant emerges in a pathogen or in the clinical setting, as well as proactively developing next-generation therapies that target these resistance determinants. Recent advances in the field highlight the promise that the next generation of resistome studies hold for characterizing and countering emerging resistance threats

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

 

Track: 18  Micro Organisms in Recent Drug Discovery

Environmental microbes are a leading source of drug discovery, and several microbial products ( anti-tumour products, antibiotics, immunosuppressant’s and others) are used frequently for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that the large number of microbes were not targeted for drug discovery. With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary way of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenario to swamped such constraints that might further expand the promise of drugs from environmental microbes

Novel species discovery

Micos from different areas (patients, geographical locations)

Genetically modified organisms

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

 

Track: 19 Current Research in Antibiotic Resistance

Antibiotic overuse and misuse has led to a growing number of bacteria in humans, animals and the environment that are resistant to life-saving antimicrobial therapies. Urgent action is needed to halt the development of resistance, and to accelerate new treatments for bacterial infection. Research includes epidemiology of both Gram-negative and Gram-positive infections, genetic mechanisms of resistance, evolution and transmission in the hospital setting, as well as the community, and antimicrobial stewardship

 

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

 

Track: 20 New antibiotics and non-antibiotic approaches

New antibiotics and non-antibiotic approaches are crucial in the fight against antibiotic resistance, a global health threat. Antibiotic resistance occurs when bacteria evolve and become resistant to the drugs designed to kill them. This makes it harder to treat infections and increases the risk of severe complications. The development of new antibiotics is essential to combat resistant bacteria. Scientists are constantly searching for novel molecules and compounds that can effectively target and kill bacteria. These new antibiotics aim to bypass existing resistance mechanisms and provide alternative treatment options. In addition to new antibiotics, non-antibiotic approaches are being explored to tackle bacterial infections. One such approach is the use of bacteriophages, which are viruses that infect and kill bacteria. Bacteriophage therapy shows promise in targeting specific bacterial strains and reducing the risk of resistance. Other non-antibiotic approaches include immunotherapy, which enhances the body's immune response to fight infections, and the use of antimicrobial peptides, which are naturally occurring molecules that can kill bacteria. Combining these new antibiotics and non-antibiotic approaches with responsible antibiotic use and infection prevention measures can help mitigate the spread of antibiotic resistance.

 

Related Societies: Alliance for the Prudent Use of Antibiotics (APUA), Centres for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Centre for a Livable Future (CLF), Infectious Diseases Society of America, The World Alliance against Antibiotic Resistance (WAAAR)

 

Track: 21 Modern Antibiotics for Various Diseases and Infections

Modern antibiotics have revolutionized the field of medicine, providing effective treatment options for various diseases and infections. These powerful drugs target and kill bacteria, helping to alleviate symptoms and prevent complications. For common bacterial infections such as urinary tract infections, respiratory infections, and skin infections, antibiotics like penicillin, cephalosporin’s, and macrolides are often prescribed. These antibiotics work by interfering with the bacteria's ability to grow and reproduce, ultimately leading to their destruction. In recent years, there have been notable advancements in antibiotic development, including the introduction of broad-spectrum antibiotics that can target a wide range of bacteria. Fluoroquinolones and carbapenems are examples of such antibiotics, often used to treat severe infections caused by multidrug-resistant bacteria. Furthermore, antibiotics like tetracyclines and sulfonamides are commonly used to treat acne and other skin conditions caused by bacteria.

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

 

Market Analysis

Antibiotic usage varies Globally:

Antibiotics changed the world. General deals in the present antibiotics and new products advertise were about $48 billion in 2019. It expanded to $51.5 billion in 2021. By 2025, it is anticipated to increase to $77.5 billion, for a 5-year compound annual growth rate (CAGR) of over 9.6%. 

 

 

Commonly used antibiotics with their increased percentage of resistance

The antibiotics market generated sales of US$52 billion in 2019 all inclusive, representing 46% of sales of anti-infective agents (which additionally incorporate antiviral medications and vaccines) and 5% of the worldwide Pharmaceutical Market. However, the antibiotics market is maturing; it demonstrated a normal yearly development of 4% in the course of recent years, contrasted and a development of 16.7% and of 16.4% for antiviral medications and vaccines, individually.

 

 

The worldwide foundational antibiotics market was esteemed at $39.6 billion in 2013 and is relied upon to reach $61.2 billion by 2025, at a CAGR of 0.8%. Since, 2015 this market apparently grows at a yearly rate of 7.6% until 2021. There are many organizations manufacturing antibiotics nowadays and there are numerous different antibiotics present in the market, for example, aminoglycoside antibiotics and it covers around 79% of the worldwide demand. In addition, alternate antibiotics, for example, pencillin have 8%, tetracyclines 4%, erythromycin 7%, streptomycin 1% and chloramnphenicol has 1 % market.

Organizations working on Antibiotics around the Globe:

  • Infectious Diseases Society of America
  • World Health Organization
  • U.S. Food and Drug Administration (FDA)
  • Center for a Livable Future (CLF)
  • Centers for Disease Control and Prevention (CDC)
  • American Medical Association
  • Animal Welfare Approved (AWA)
  • Center for Food Safety
  • Center for Science in the Public Interest (CSPI)
  • Food Animal Concern Trust (FACT)
  • The Humane Society of the United States (HSUS)
  • The Pew Charitable Trusts
  • Food and Water Watch
  • Healthy Food Action
  • Keep Antibiotics Working (KAW)
  • Natural Resources Defense Council (NRDC)
  • American Nurses Association
  • American Public Health Association
  • Institute of Medicine, National Academies of Science
  • American Society for Microbiology  

 

To Collaborate Scientific Professionals around the World

Conference Date November 25-26, 2024

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Supported By

The Journal of Antivirals & Antiretrovirals Journal of Pharmacovigilance Journal of Bioequivalence & Bioavailability

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by


Keytopics

  • 1. Antibiotic Resistance
  • 10. Sulfonamides
  • 100. Centers For Disease Control And Prevention (CDC)
  • 11. Aminoglycosides
  • 12. Clindamycin
  • 13. Metronidazole
  • 14. Vancomycin
  • 15. Carbapenems
  • 16. Beta-lactam
  • 17. Broad-spectrum Antibiotics
  • 18. Narrow-spectrum Antibiotics
  • 19. Antibiotic Therapy
  • 2. Bactericidal
  • 20. Antimicrobial Stewardship
  • 21. Prophylactic Antibiotics
  • 22. Antibiotic Misuse
  • 23. MRSA (Methicillin-resistant Staphylococcus Aureus)
  • 24. VRE (Vancomycin-resistant Enterococcus)
  • 25. ESBL (Extended-spectrum Beta-lactamases)
  • 26. CRE (Carbapenem-resistant Enterobacteriaceae)
  • 27. MDR (Multidrug-resistant)
  • 28. Superbugs
  • 29. Infection Control
  • 3. Bacteriostatic
  • 30. Bacterial Infection
  • 31. Viral Infection
  • 32. Fungal Infection
  • 33. Nosocomial Infection
  • 34. Community-acquired Infection
  • 35. Urinary Tract Infection
  • 36. Respiratory Tract Infection
  • 37. Skin Infection
  • 38. Sepsis
  • 39. Septicemia
  • 4. Penicillin
  • 40. Pyelonephritis
  • 41. Otitis Media
  • 42. Sinusitis
  • 43. Pneumonia
  • 44. Bronchitis
  • 45. Tuberculosis
  • 46. Dosing Regimen
  • 47. Pharmacokinetics
  • 48. Pharmacodynamics
  • 49. Therapeutic Index
  • 5. Amoxicillin
  • 50. Side Effects
  • 51. Allergic Reaction
  • 52. Anaphylaxis
  • 53. Clostridioides Difficile
  • 54. Gut Microbiome
  • 55. Dysbiosis
  • 56. Probiotics
  • 57. Antibiotic-associated Diarrhea
  • 58. Empiric Therapy
  • 59. Targeted Therapy
  • 6. Cephalosporins
  • 60. Minimum Inhibitory Concentration (MIC)
  • 61. Zone Of Inhibition
  • 62. Synergy
  • 63. Antagonism
  • 64. Combination Therapy
  • 65. Monotherapy
  • 66. Prophylaxis
  • 67. Post-antibiotic Effect
  • 68. Resistance Mechanisms
  • 69. Efflux Pumps
  • 7. Macrolides
  • 70. Biofilm
  • 71. Plasmid
  • 72. Horizontal Gene Transfer
  • 73. Mutation
  • 74. Genetic Resistance
  • 75. Antibiogram
  • 76. Culture And Sensitivity
  • 77. Disk Diffusion Method
  • 78. Broth Dilution Method
  • 79. E-test
  • 8. Tetracyclines
  • 80. Antibiotic Discovery
  • 81. Natural Antibiotics
  • 82. Synthetic Antibiotics
  • 83. Semisynthetic Antibiotics
  • 84. Antibiotic Pipeline
  • 85. Clinical Trials
  • 86. FDA Approval
  • 87. Off-label Use
  • 88. Prescription Guidelines
  • 89. Over-the-counter Antibiotics
  • 9. Fluoroquinolones
  • 90. Veterinary Antibiotics
  • 91. Aquaculture Antibiotics
  • 92. Agricultural Antibiotics
  • 93. Environmental Impact
  • 94. Wastewater Treatment
  • 95. Antimicrobial Peptides
  • 96. Phage Therapy
  • 97. Resistance Surveillance
  • 98. Public Health
  • 99. World Health Organization (WHO)